

Supplementary Information

Genome-wide association study of febrile seizures identifies seven new loci implicating fever response and neuronal excitability genes

Skotte et al.

Table of contents


Supplementary Figures

Supplementary Figure 1:	Study design	3
Supplementary Figure 2:	Statistical power curves for the discovery stage analyses	4
Supplementary Figure 3:	Regional association plots of the seven novel febrile seizures loci	5
Supplementary Figure 4:	Regional association plots of all febrile seizures loci, conditional on the lead SNP at each locus	8
Supplementary Figure 5:	Forest plots of the seven novel febrile seizures loci	12
Supplementary Figure 6:	DEPICT analysis of enrichment	14
Supplementary Figure 7:	Forest plots of iPSYCH study subgroup results for all loci	15
Supplementary Figure 8:	iPSYCH study selection scheme for febrile seizures cases and controls	18


Supplementary Tables

Supplementary Table 1:	Analysis of interaction between genotype and sex at the seven novel febrile seizures loci	19
Supplementary Table 2:	Analysis of alternative genetic models at the seven novel febrile seizures loci	19
Supplementary Table 3:	Discovery stage association results for variants at the seven novel and four known febrile seizures loci	20
Supplementary Table 4:	eQTL results based on the BRAINEAC, DICE, eQTL Catalogue, eQTLGen, and GTEx/v8 databases for variants at all febrile seizures loci	20
Supplementary Table 5:	GWAS catalog associations for variants at all febrile seizures loci	20
Supplementary Table 6:	Febrile seizures association analysis of exome sequencing data	21
Supplementary Table 7:	Statistical fine mapping results for the seven novel loci	21
Supplementary Table 8:	Association results in the iPSYCH and DBDS cohorts for variants known to be distinctly associated with febrile seizures occurring after MMR vaccination	21
Supplementary Table 9:	Association results for the seven novel febrile seizures loci in the SSI discovery cohort taking MMR vaccination data into account	22




Supplementary Figures







Supplementary Figure 1. Overview of Study Design






Supplementary Figure 2. Power simulations based on the discovery stage sample size of 4,502 cases and 51,049 controls. **a**, Simulations for variants with population risk allele frequencies of 10% (dotted line), 20% (dashed line) and 30% (full line), and **b**, for variants with frequencies of 1% (dashed line) and 5% (full line). Simulations were done assuming a febrile seizure prevalence of 3.6%, a log-additive genetic model and a significance level of $\alpha=5 \times 10^{-8}$, for varying effect sizes. The x-axis shows the effect size in terms of the odds ratio underlying the simulation, while the y-axis shows the power (the fraction of the simulations with an α -significant P value for an estimated OR in the direction of the simulated OR).




a**b****c**




d**e****f**


g

Supplementary Figure 3. Regional association plots of the seven novel loci for febrile seizures. Each circle represent a variant in the GWAS meta-analysis; the position along the x-axis represent the genomic location, the position along the y-axis shows the $-\log_{10} P$ value, the color indicates the r^2 value between the variant and the lead variant at each locus. **a**, *PTGER3* locus, lead variant rs3001038, **b**, *IL10* locus, lead variant rs1554286, **c**, *BSN* locus, lead variant rs11917431, **d**, *ERC2* locus, lead variant rs4974130, **e**, *GABRG2* locus, lead variant rs1997583, **f**, *MAP3K9* locus, lead variant rs244620, and **g**, *HERC1* locus, lead variant rs4267257.








d**e****f**

g**h****i**








Supplementary Figure 4. Regional association plots of the seven novel and four known loci for febrile seizures, conditioning on the lead SNP at each locus. Each circle represent a variant in the GWAS meta-analysis; the position along the x-axis represent the genomic location, the position along the y-axis shows the $-\log_{10} P$ value, the color indicates the r^2 value between the variant and the lead variant at each locus. **a**, *PTGER3* locus, conditioned on lead variant rs3001038, **b**, *IL10* locus, conditioned on lead variant rs1554286, **c**, *BSN* locus, conditioned on lead variant rs11917431, **d**, *ERC2* locus, conditioned on lead variant rs4974130, **e**, *GABRG2* locus, conditioned on lead variant rs1997583, **f**, *MAP3K9* locus, conditioned on lead variant rs244620, **g**, *HERC1* locus, conditioned on lead variant rs4267257, **h**, *SCN2A* locus, conditioned on lead variant rs16850528 and neighboring *SCN1A* lead variant rs11904006, **i**, *SCN1A* locus, conditioned on lead variant rs11904006 and neighboring *SCN2A* lead variant rs16850528, **j**, *ANO3* locus, conditioned on lead variant rs114444506, **k**, 12q21.33 locus, conditioned on lead variant rs71909799.










Supplementary Figure 5. Forest plots showing associations between the robustly replicating SNP at each of the seven novel loci and febrile seizures in contributing cohorts and in combined analyses. The plots show odds ratio estimates with 95% confidence intervals. **a**, *PTGER3* locus, rs3001038, **b**, *IL10* locus, rs1518111, **c**, *BSN* locus, rs11917431, **d**, *ERC2* locus, rs4974130, **e**, *GABRG2* locus, rs1997583, **f**, *MAP3K9* locus, rs244620, and **g**, *HERC1* locus, rs62023078.










Supplementary Figure 7. Analyses of heterogeneity between subgroups of the iPSYCH study for the seven novel and four known febrile seizures loci. The forest plots show odds ratio estimates with 95% confidence intervals. **a**, *PTGER3* locus, rs3001038, **b**, *IL10* locus, rs1554286, **c**, *BSN* locus, rs11917431, **d**, *ERC2* locus, rs4974130, **e**, *GABRG2* locus, rs1997583, **f**, *MAP3K9* locus, rs244620, **g**, *HERC1* locus, rs4267257, **h**, *SCN2A* locus, rs16850528, **i**, *SCN1A* locus, rs11904006, **j**, *ANO3* locus, rs114444506, **k**, 12q21.33 locus, rs71909799.



Supplementary Figure 8. Selection of febrile seizures cases and controls in the iPSYCH study.

Supplementary Tables

Supplementary Table 1

Analysis of interaction between genotype and sex for the seven novel febrile seizures loci in the SSI and iPSYCH discovery cohorts individually and combined by meta-analysis.

Chr	Position	SNP	Allele1	Allele2	Sample_set	Beta_SNP	SE_SNP	P_SNP	Beta_sex	SE_sex	P_sex	Beta_int	SE_int	P_int
1	71163715	rs3001038	A	G	SSI	0.097	0.054	0.0712	-0.247	0.098	0.012	0.154	0.079	0.05
					iPSYCH	0.132	0.038	0.000442	-0.179	0.075	0.017	0.027	0.059	0.648
					Meta							0.073	0.047	0.122
1	206944645	rs1518111	T	C	SSI	0.141	0.067	0.0356	-0.093	0.068	0.172	-0.007	0.097	0.942
					iPSYCH	0.177	0.046	0.000112	-0.143	0.052	0.006	-0.025	0.073	0.733
					Meta							-0.018	0.058	0.751
3	49644012	rs11917431	T	C	SSI	0.061	0.058	0.293	-0.176	0.075	0.019	0.142	0.085	0.094
					iPSYCH	0.147	0.04	0.000281	-0.173	0.058	0.003	0.03	0.064	0.638
					Meta							0.07	0.051	0.167
3	56298138	rs4974130	C	T	SSI	0.361	0.105	0.000556	-0.073	0.059	0.212	-0.155	0.154	0.314
					iPSYCH	0.314	0.073	1.71E-05	-0.143	0.045	0.001	-0.078	0.116	0.505
					Meta							-0.106	0.093	0.255
5	161508503	rs1997583	T	A	SSI	0.239	0.09	0.00763	-0.072	0.061	0.24	-0.119	0.128	0.353
					iPSYCH	0.223	0.066	0.000675	-0.148	0.047	0.002	-0.028	0.104	0.79
					Meta							-0.064	0.081	0.428
14	71323249	rs244620	C	T	SSI	0.053	0.056	0.343	-0.181	0.093	0.051	0.096	0.081	0.235
					iPSYCH	0.158	0.038	2.66E-05	-0.105	0.071	0.138	-0.05	0.059	0.404
					Meta							0.001	0.048	0.978
15	64132818	rs62023078	G	T	SSI	0.237	0.074	0.00133	0.074	0.189	0.693	-0.101	0.107	0.349
					iPSYCH	0.133	0.051	0.00965	-0.187	0.143	0.192	0.02	0.081	0.808
					Meta							-0.024	0.065	0.711

Chr, chromosome; Beta_SNP, main effect of SNP with corresponding standard error (SE_SNP) and *P* value (P_SNP); Beta_sex, main effect of sex with corresponding standard error (SE_sex) and *P* value (P_sex); Beta_int, interaction effect between SNP and sex with corresponding standard error (SE_int) and *P* value (P_int).

Supplementary Table 2

Analysis of alternative genetic models for the seven novel febrile seizures loci in the SSI and iPSYCH discovery cohorts. The table shows effect estimates and corresponding standard errors and *P* values from an additive genetic model (ADD), a recessive model (REC), a dominant model (DOM), and a full genotype model (AB and BB); *P* values from ANOVA tests of the full genotype model versus the null model, the full model versus the additive model, the full model versus the recessive model, and the full model versus the dominant model. **Table supplied as an additional Excel spreadsheet (online).**

Supplementary Table 3

Discovery stage association results for 1843 variants with $P < 1 \times 10^{-4}$ at the seven novel and four known febrile seizures loci. The table is sorted by chromosome and base pair position (GRCh37/hg19) and shows effect and alternative allele; meta-analysis results; SSI discovery cohort results; iPSYCH discovery cohort results; variant annotation and nearest gene; exonic variant class and affected transcripts; SIFT, PolyPhen-2, and FATHMM scores and predictions of missense mutation pathogenicity. Results for the different loci are separated by bold lines. **Table supplied as an additional Excel spreadsheet (online).**

Supplementary Table 4

eQTL results based on the BRAINEAC, DICE, eQTL Catalogue, eQTLGen, and GTEx/v8 databases for variants associated with febrile seizures with $P < 1 \times 10^{-4}$ at the seven novel and four known loci. The table is sorted by chromosome and base pair position (GRCh37/hg19) and shows febrile seizures variant, risk allele and discovery P value; eQTL database and tissue; Ensembl gene ID, eQTL tested allele, P value, effect size, and false discovery rate; febrile seizures risk increasing allele; aligned direction between disease risk and gene expression; variant ID and RefSeq gene name. Results for the different loci are separated by bold lines. **Table supplied as an additional Excel spreadsheet (online).**

Supplementary Table 5

GWAS catalog associations ($P < 5 \times 10^{-8}$) for variants associated with febrile seizures with $P < 1 \times 10^{-4}$ at the seven novel and four known loci. The table is sorted by chromosome and base pair position (GRCh37/hg19) and shows febrile seizures variant, risk allele and discovery P value; PubMed ID for the relevant GWAS article; trait in the GWAS catalog; SNP and effect allele; type of variant; risk allele frequency; P value and accompanying description; odds ratio or beta estimate and 95% confidence interval. Results for the different loci are separated by bold lines. **Table supplied as an additional Excel spreadsheet (online).**

Supplementary Table 6

Febrile seizures association analysis of exome sequencing data. For each novel locus, results are shown from gene-based rare-variants association tests for genes within 1 MB of the top SNP at the locus, using the SKAT-O approach. CHROM, BEGIN and END denote chromosomal position on GRCh37/hg19 and NS denotes number of samples. The fraction of individuals with rare variants (FRAC_WITH_RARE), the number of variants (NUM_ALL_VARS), the number of variants after data cleaning (NUM_PASS_VARS) and the number of singleton variants (NUM_SING_VARS) in each gene are given, along with the SKAT-O *P* value and the optimal weight (STATRHO) for the test. Results for each locus is shown in a separate tab. **Table supplied as an additional Excel spreadsheet (online).**

Supplementary Table 7

Credible sets of variants with highest posterior probability of being causal at each of the seven novel loci. The sets were found under the assumption of one causal variant at each locus and the posterior probability of one causal variant compared to none is shown as well as the corresponding Bayes factor. In addition minimum, average and median absolute correlation between SNPs in the credible set are shown. The SNPs included in each credible set are listed in order of highest posterior inclusion probability, and the smallest set of SNPs with posterior probabilities summing to 0.95 defines the credible set. Results for each locus is shown in a separate tab. **Table supplied as an additional Excel spreadsheet (online).**

Supplementary Table 8

Association results in the iPSYCH and DBDS cohorts for variants at the *IFI44L* and *CD46* loci known to be distinctly associated with febrile seizures occurring after MMR vaccination.

Chr	Position	SNP	Alleles		Locus	Cohort	Frequency		Number		OR (95% CI)	<i>P</i>
			Effect	Alt.			Cases	Controls	Cases	Controls		
1	79093818	rs273259	A	G	<i>IFI44L</i>	iPSYCH	0.715	0.699	2511	46952	1.08 (1.01-1.15)	0.02
						DBDS	0.694	0.698	922	28558	0.98 (0.89-1.09)	0.73
1	208014922	rs1318653	T	C	<i>CD46</i>	iPSYCH	0.77	0.765	2511	46952	1.03 (0.96-1.10)	0.44
						DBDS	0.763	0.764	921	28711	0.99 (0.89-1.11)	0.89

Supplementary Table 9

Association results for the seven novel febrile seizures loci in the SSI discovery cohort taking data about temporal relationship to measles, mumps, and rubella (MMR) vaccination into account.

Chr	Position (bp)	SNP (effect allele/alternative allele)	Analysis	Effect allele frequency cases	Effect allele frequency controls	Number of cases	Number of controls	OR	P value	P interaction
1	71163715	rs3001038 (A/G)	MMR+ vs. controls	0.515	0.486	925	4097	1.13 (1.02-1.25)	0.0185	
			MMR+ vs. MMR-	0.515	0.538	925	1066	0.90 (0.79-1.03)	0.119	
			MMR- vs. controls	0.538	0.486	1066	4097	1.23 (1.12-1.36)	2.35E-05	
			All FS vs. controls	0.527	0.486	1991	4097	1.19 (1.10-1.28)	1.47E-05	
1	206944645	rs1518111 (T/C)	MMR+ vs. controls	0.223	0.194	925	4097	1.21 (1.07-1.37)	0.00309	0.0693
			MMR+ vs. MMR-	0.223	0.208	925	1066	1.09 (0.94-1.28)	0.252	
			MMR- vs. controls	0.208	0.194	1066	4097	1.10 (0.97-1.24)	0.125	
			All FS vs. controls	0.215	0.194	1991	4097	1.15 (1.04-1.26)	0.00453	
3	49644012	rs11917431 (T/C)	MMR+ vs. controls	0.312	0.282	925	4097	1.16 (1.04-1.29)	0.00879	0.0569
			MMR+ vs. MMR-	0.312	0.305	925	1066	1.04 (0.91-1.19)	0.557	
			MMR- vs. controls	0.305	0.282	1066	4097	1.11 (1.00-1.23)	0.0446	
			All FS vs. controls	0.308	0.282	1991	4097	1.13 (1.04-1.23)	0.00279	
3	56298138	rs4974130 (C/T)	MMR+ vs. controls	0.082	0.058	925	4097	1.47 (1.21-1.78)	9.62E-05	0.817
			MMR+ vs. MMR-	0.082	0.07	925	1066	1.20 (0.95-1.52)	0.128	
			MMR- vs. controls	0.07	0.058	1066	4097	1.23 (1.01-1.49)	0.0351	
			All FS vs. controls	0.076	0.058	1991	4097	1.34 (1.15-1.55)	0.000166	
5	161508503	rs1997583 (T/A)	MMR+ vs. controls	0.105	0.092	925	4097	1.16 (0.98-1.37)	0.0893	0.138
			MMR+ vs. MMR-	0.105	0.111	925	1066	0.94 (0.77-1.15)	0.56	
			MMR- vs. controls	0.111	0.092	1066	4097	1.23 (1.06-1.44)	0.00749	
			All FS vs. controls	0.108	0.092	1991	4097	1.20 (1.06-1.36)	0.00467	
14	71323249	rs244620 (C/T)	MMR+ vs. controls	0.478	0.447	925	4097	1.15 (1.04-1.28)	0.00899	0.936
			MMR+ vs. MMR-	0.478	0.462	925	1066	1.07 (0.94-1.22)	0.297	
			MMR- vs. controls	0.462	0.447	1066	4097	1.06 (0.96-1.18)	0.222	
			All FS vs. controls	0.469	0.447	1991	4097	1.10 (1.02-1.19)	0.0151	
15	64132818	rs62023078 (G/T)	MMR+ vs. controls	0.848	0.823	925	4097	1.20 (1.05-1.39)	0.00945	0.458
			MMR+ vs. MMR-	0.848	0.849	925	1066	0.99 (0.82-1.18)	0.875	
			MMR- vs. controls	0.849	0.823	1066	4097	1.21 (1.06-1.39)	0.00422	
			All FS vs. controls	0.848	0.823	1991	4097	1.21 (1.09-1.34)	0.000395	

Chr, chromosome; bp, base pair; OR, odds ratio (with 95% confidence interval); P interaction, P value for test of interaction between genotype and vaccination in a model including all febrile seizures cases and controls from the SSI discovery cohort; MMR+, MMR-related febrile seizure cases (febrile seizures occurring in a risk window of 9 to 14 days after the date of MMR vaccination); MMR-, MMR-unrelated febrile seizure cases (febrile seizures occurring 6 weeks or more after vaccination or in an infant with no vaccine exposure); FS, febrile seizures. Controls in the MMR+ vs. MMR- analyses are febrile seizure cases unrelated to MMR vaccination.